Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment

(2019) Xue Yang et al.   MEDICINE

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

(2019) Olga P. Nyssen et al.   HELICOBACTER

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Tu1299 - Vonoprazan-Based Dual Therapy with Amoxicillin is as Effectve as the Triple Therapy for the Eradication of H. Pylori

(2018) Takahisa Furuta et al.   GASTROENTEROLOGY

Helicobacter pylorieradication treatment and the risk of gastric adenocarcinoma in a Western population

(2018) Eva Doorakkers et al.   GUT

Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer

(2018) Il Ju Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study

(2018) Andrea Iannone et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection

(2018) Mei-Jyh Chen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers

(2018) Takuji Gotoda et al.   HELICOBACTER

Second-line rescue treatment of Helicobacter pylori infection: Where are we now?

(2018) Te-Fu Lin et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

(2017) James K.Y. Hooi et al.   GASTROENTEROLOGY

Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children

(2017) Chika Kusano et al.   JOURNAL OF GASTROENTEROLOGY

Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance

(2017) Angel Cosme et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization

(2017) Amin Talebi Bezmin Abadi   WORLD JOURNAL OF GASTROENTEROLOGY

Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection

(2017) Nazlı Arslan et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy?

(2017) Enzo Ierardi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment ofHelicobacter pyloriinfection

(2015) J.-M. Liou et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

(2015) Jyh-Chin Yang et al.   Clinical Gastroenterology and Hepatology

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-lineHelicobacter pyloritherapy

(2015) Wei Zhang et al.   GUT

Primary antibiotic resistance ofHelicobacter pyloristrains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study

(2015) Yue-Xi Zhang   WORLD JOURNAL OF GASTROENTEROLOGY

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study

(2015) Jyh-Ming Liou et al.   PLoS One

Antibiotic Resistance ofHelicobacter PyloriIsolated in the Southeast Coastal Region of China

(2013) Peng Su et al.   HELICOBACTER

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Helicobacter pyloriInfection

(2010) Kenneth E.L. McColl   NEW ENGLAND JOURNAL OF MEDICINE